Omega Pharma has moved its entire portfolio into the new UK healthcare practice at GolinHarris, following the agency's acquisition of Virgo Healthcare last year.
The pharma company has moved its business out of Virgo and into Golin's healthcare practice, which opened for business last week. Sian Boisseau, former director of consumer health at Virgo, is leading the account.
Golin's healthcare team of five is charged with raising awareness of Omega Pharma's over-the-counter brands, targeting both consumer and trade media, as the company looks to become one of the top three in its sector in five years.
Omega Pharma's portfolio includes sleeping aid brand Nytol, pain relief brand Solpadeine, and mosquito repellent Jungle Formula.
While the healthcare practices of Virgo and Golin sit alongside each other within parent company Interpublic Group, Virgo's offices remain seperate. The Omega Pharma account was moved out of the building to avoid conflicts of interest with Virgo's other over-the-counter clients, such as Reckitt Benckiser.
Boisseau continues to report to Angie Wiles and Sarah Matthew, joint global healthcare practice leaders at Golin and joint chief executives at Virgo Healthcare.
Wiles said the two agencies would be “collaborating where appropriate but [remain] separate where client conflicts exist.”
“It is a natural, but important, progression for us to establish a healthcare team within GolinHarris London that can also deliver the uncompromised health communications for which Virgo has become known,” she added.
This story originally appeared on the website of PRWeek UK, the sister magazine of PRWeek at Haymarket Media.